Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.4.19 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Masahiro Akada and 9 co-authors. Institution: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. Major MEDLINE topics: Angiogenesis Inhibitors, Wet Macular Degeneration. 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To characterize age-specific changes in the prevalence and treatment burden of neovascular AMD (nAMD) from 2014 to 2019 in a super-aged society and to assess whether comorbidities contribute to this increase.
Methods
We performed a nationwide repeated cross-sectional study using Japan's national claims database (>95% population coverage). Adults aged ≥40 years in 2014 and 2019 were included to estimate age-stratified nAMD prevalence. Treatment burden was evaluated as the total number of nAMD-related treatment claims and mean administrations among users of each agent. Diabetes, hypertension, and dyslipidemia were identified from claims. Multivariable logistic regression compared nAMD cases with controls and assessed whether comorbidity adjustment attenuated the odds of nAMD in 2019 versus 2014.
Results
We identified 76,125 cases in 2014 and 125,190 in 2019; age-standardized prevalence increased from 101.3 to 152.4 per 100,000. Prevalence peaked at ages 80-84 in both years but increased most steeply among those ≥75 years (62.9%). Total treatment claims increased markedly, driven primarily by aflibercept. Among users of each agent, mean administrations increased modestly. Comorbidities were associated with higher odds of nAMD, but adjusting for them did not change the higher odds of nAMD in 2019 compared with in 2014.
Conclusions
Between 2014 and 2019, the prevalence and treatment burden of nAMD increased substantially in Japan, with a disproportionate rise among older age groups in a super-aged population. Comorbidities did not account for the temporal increase, suggesting that factors beyond aging and comorbidity are contributing to the growing burden.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Center for Innovative Research and Education in Data Science, Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, Japan.
Cite
APA
Akada, M., Ideyama, M., Kido, A., Miyata, M., Ueda-Arakawa, N., Tamura, H., Ooto, S., Miyake, M., Tsujikawa, A., & Hata, M. (2026). Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.4.19
Vancouver
Akada M, Ideyama M, Kido A, Miyata M, Ueda-Arakawa N, Tamura H, et al. Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.4.19
BibTeX
@article{Akada2026,
author = {Akada, Masahiro and Ideyama, Midori and Kido, Ai and Miyata, Manabu and Ueda-Arakawa, Naoko and Tamura, Hiroshi and Ooto, Sotaro and Miyake, Masahiro and Tsujikawa, Akitaka and Hata, Masayuki},
title = {Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.4.19}
}
EUVIMED